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Pluripotent stem cell (PSC) technologies are becoming a key asset for deciphering pathological cascades
and for developing new treatments against many neurodegenerative disorders, including Huntington’s
disease (HD). This perspective discusses the challenges and opportunities facing the use of PSCs for treating
HD, focusing on four major applications: namely, the use of PSCs as a substitute source of human striatal
cells for current HD cell therapy, as a cellular model of HD for the validation of human-specific gene therapies,
for deciphering molecular mechanisms underlying HD, and in drug discovery.Human pluripotent stem cell (PSC) lines are rapidly changing the
strategies scientists can implement to understand pathological
mechanisms and cure monogenic diseases. Pluripotency is
key to the derivation of cell phenotypes that are relevant for
disease, including those that are essentially inaccessible in any
other way (e.g., postmitotic neurons), and unlimited self-renewal
provides easy access to the biological resource of interest.
Selection of donors with specific genotypes opens up the path
for analysis of mechanisms associated with the presence of
a variety of genetic determinants. The challenges associated
with using disease-specific PSCs to create new avenues for
therapeutic interventions have been outlined in detail in light of
the intense interest in this area (for review, see Colman and
Dreesen, 2009). Updates pointing to the need for caution in
handling these extraordinary biological resources and in inter-
preting related data are also posted frequently. These reports
do not present insurmountable roadblocks, but they have
raised concerns about the actual capacity of PSC lines to mimic
disease mechanisms without artifactual interference from
new genetic and epigenetic abnormalities (Yamanaka, 2012).
Considering the limited number of individual lines often used to
model disease mechanisms and the high incidence of line-to-
line variation, the possibility of wrongly attributing to a disease-
causing mutation a phenotype that is in fact the result of the
uneven distribution of such alterations in control and diseased
groups needs to be considered seriously.When disease-specific
hPSCs are used to identify novel aspects of disease mecha-
nisms, rather than simply to replicate already known pathological
features, internal (isogenic) control experiments such as genetic
correction or more classical gain- and loss-of-function experi-
ments are extremely valuable.
The current tsunami of studies and publications on genetic
diseases is a direct consequence of what can be considered
a new era for biomedical research. There are several ways in
which this growth in opportunities has changed and may impact
future research on molecular mechanisms and therapies of
Huntington’s disease (HD) (Figure 1). HD is a devastating neuro-
degenerative disorder with autosomal-dominant transmission,
caused by mutations that expand a CAG repeat tract and leadto the presence of long stretches of polyglutamine in the
Huntingtin protein encoded by theHTT (IT15) gene (The Hunting-
ton’s Disease Collaborative Research Group, 1993). HD involves
progressive neuronal loss in the striatum, the cortex and the
globus palidus. The signaling pathways linking the genetic basis
of HD to neuronal dysfunction and death are still poorly under-
stood and likely involve both ‘‘a toxic gain of function’’ of the
mutant HTT and ‘‘a loss of function’’ of the normal HTT. There
is a wealth of cellular models of HD produced by transfection/
infection or from transgenic rodents expressing, often as a third
allele, fragments of or full-length HTT mutant protein. However,
these models fail to replicate the pathologically relevant pheno-
types that stem from both the loss of human wild-type HTT and
the expression of full-length mutant HTT, which together
produce the striatal degenerative defects. Several very recent
publications (Camnasio et al., 2012; Feyeux et al., 2012; Juop-
peri et al., 2012) have taken advantage of the properties of
disease-specific human PSCs to explore the pathological mech-
anisms of HD using unbiased transcriptomic approaches or
hypothesis-driven strategies based on prior knowledge of HD-
mediated neurodegeneration. The two papers published in this
issue of Cell Stem Cell by An and coauthors (An et al., 2012)
and The HD iPSC Consortium (2012) have taken a similar
approach, combining transcriptomic analyses and assessment
of classical HD phenotypes (see Table 1) to evaluate the capacity
of patient-derived iPSCs to model HD. A major difference
between the two current publications is in their approaches
toward obtaining biological controls. An and colleagues essen-
tially started from a single HD-iPSC line, derived from a patient
with a juvenile form of HD and genetically engineered using
homologous recombination to produce two genetically cor-
rected clones carrying normal CAG counts in both HTT alleles.
In addition to raising the possibility of autologous iPSC therapy,
the corrected clones provided the authors with HD and control
lines with identical genetic backgrounds, thus allowing them to
show that the specific genetic correction normalized pathogenic
HD signaling pathways and reversed disease phenotypes. In
contrast, the approach of The HD iPSC Consortium relied on
the derivation of eight HD-iPSC clones derived from six distinctCell Stem Cell 11, August 3, 2012 ª2012 Elsevier Inc. 153
induced 
pluripotency
hESC
derivation
  HD - iNSC or -iN
direct lineage 
conversionHD human 
somatic cells
Genetic corrections
G.O.F / L.O.F
HD human 
inner cell mass
Biopsy
I.V.F egg
Preimplantation
Genetic Diagnosis
HD - Patient
Medical history
Gamete Gamete
HD - hESCs HD - hiPSCs
HD - NSCs
HD-hPSC
non-neural derivatives
in vitro differentiation
HD - Neurons
Humanized 
HD animal model
(via transplantation)
HD - Astrocytes
BIOLOGICAL
THERAPIES
HUNTINGTON DISEASE 
HUMAN STEM CELL 
THERAPEUTIC APPLICATIONS 
PATHOLOGICAL 
CELLULAR MODEL
DRUG SCREENING
AND DISCOVERY
Figure 1. Origin and Possible Applications for HD of Wild-Type and Disease-Specific Human PSCs
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fected people, including one HD patient’s sibling. Both studies
identified genes that are differentially expressed in cells carrying
a HTT mutation (see Table 1), thus creating a path for genotypic/
phenotypic analyses that may reveal discrete links between
molecular alterations and abnormal cell functioning.
PSC-Based Therapy for HD
Development of technologies that now provide unlimited access
to hPSCs (hESCs: Thomson et al., 1998; and hiPSCs: Takahashi
et al., 2007; Yu et al., 2007) has radically changed the outlook for
using cell therapy to treat HD. HD is a hallmark striatal neurode-
generative disease and is limited to lesions within this distinct
region. It is thought that the relative spatial selectivity of the neu-
rodegeneration in HD explains why experimental therapy with
fetal striatal cells is effective for the reconstruction and recovery
of rodent and nonhuman primates with drug-induced striatal
lesions (Kendall et al., 1998; Palfi et al., 1998; Peschanski
et al., 1995). Building on these achievements, similar surgical
approaches using fetal striatal tissue have been tested clinically154 Cell Stem Cell 11, August 3, 2012 ª2012 Elsevier Inc.in humans and represent, for the moment, the only therapeutic
intervention that has demonstrated significant and long-lasting
functional benefits in HD patients (Bachoud-Le´vi et al., 2000,
2006). Considering the limited number of HD patients that have
actually benefited from transplantation with fetal cells, the
conclusive assessment of the net benefit of cell transplantation
in HD awaits the results of larger clinical trials, one of which is
ongoing (Dunnett and Rosser, 2011; Freeman et al., 2011). In
addition, the logistical difficulties associated with the acquisition
and preparation of human fetal tissues hamper clinical applica-
tion because they dramatically reduce the amount of donor
tissue and, as a consequence, the number of patients eligible
for this therapy. This challenge has fuelled the search for alterna-
tive cellular sources for treating HD and has led to the belief
that hPSCs are prime candidates for such therapies. The current
clinical standard for promoting striatal repair and corresponding
symptomatic improvement is the transplantation of cell suspen-
sions obtained from 7- to 10-week-old ganglionic eminences.
The challenge for using hPSC derivatives for HD therapy is
then to match or surpass the degree of functional brain repair
Table 1. List of Published HD Mutation Phenotypes in HD-hPSC Derivatives
Function or Marker Phenotype Assay(s) < >
Number of Lines,
WT versus HD Complementary Assays Reference
Biomarkers of HD (validation of existing targets)
CAG instability hPSC, NSC,
neuron
CAGs counts in HTT mutant alleles = n/a (Camnasio et al., 2012; The HD iPSC
Consortium, 2012; Jeon et al., 2012)
NSC CAGs counts in HTT mutant alleles HD > WT n/a (The HD iPSC Consortium, 2012;
Niclis et al., 2009)
HTT aggregates NPC IF-detection of mutant HTT aggregates absent 2 versus 2 + 2 (The HD iPSC Consortium, 2012)
iPSC, NSC,
neuron
IF-detection of mutant HTT aggregates present 1 versus 1 detected only with MG132 or in vivo
after long-term differentiation
(Jeon et al., 2012)
Cell death NSC caspase 3/7 activity, condensed
or Tunel+ nuclei
HD > WT 1 versus 3 BDNF withdrawal, G.O.F.
Nter-17Q/134Q
(The HD iPSC Consortium, 2012)
NSC caspase 3/7 activity, condensed
or Tunel+ nuclei
HD > WT 1 + 2* versus 1 not detected in iPSCs (An et al., 2012; Park et al., 2008;
Zhang et al., 2010)
iPSC caspase 3/7 activity, condensed
or Tunel+ nuclei
HD = WT 1 versus 2 (Camnasio et al., 2012)
Calcium homeostasis NSC % Ca2+ dyshomeostasis
(glutamate induced)
HD > WT 1 versus 2 (The HD iPSC Consortium, 2012)
Energy/mitochondria NSC oxygen consumption rate (upon
FCCP addition)
WT > HD 1 versus 1 (An et al., 2012)
NSC relative [ATP] and ATP/ADP ratio WT > HD 2 versus 2 + 2 (The HD iPSC Consortium, 2012)
Cell-cell adhesion NSC reaggregation assay (clump size at 12 hr) WT > HD 2 versus 2 + 2 (The HD iPSC Consortium, 2012)
Degradation pathways astrocyte cacuole detection (electron clear) HD > WT 1 versus 2 not detected in neurons (Juopperi et al., 2012)
iPSC and
neuron
lysotracker assay (sucrose induced) HD > WT western blot LC3 (Camnasio et al., 2012)
New targets identification
Proteomics NSC iTRAQ method: 356 upregulated/191
downregulated proteins
HD < > WT 1 versus 1 pathways from transcriptomic
data (e.g BDNF, Trk)
(The HD iPSC Consortium, 2012)
Transcriptomics NSC hierarchical clustering, differentially
expressed genes (FC > 2: 1,601
dysregulated genes), pathway analyses
HD < > WT 2 versus 3 QRT-PCR validation, pathways
from iTRAQ data
(The HD iPSC Consortium, 2012)
NSC and
hESC
differentially expressed genes (FC > 2: 7
dysregulated genes), pathway analyses
HD < > WT 5 versus 6 hESC and NSC analyses, QRT-PCR
validation, hESCs/NSCs/neurons,
protein validation, G.O.F
Nter-18Q/82Q, L.O.F. shHTT,
QRT-PCR and protein validation
(Feyeux et al., 2012)
iPSC differentially expressed genes (>2,500
dysregulated genes)
HD < > WT 1 versus 1 (An et al., 2012)
iPSC hierarchical clustering (no separation),
differentially expressed genes (259
dysregulated genes), pathway analyses
HDcorr
< > HD
1 + 2* versus 1 QRT-PCR validation: cadherin,
TGF-b in (iPSCs and NSCs),
N-cadherin protein level
(An et al., 2012)
*Isogenic genetic correction.
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Perspectivecurrently achieved in HD patients using fetal cells while over-
comingmajor hurdles that have been identified, namely logistics,
quality control, immunogenicity, and safety (Nicoleau et al.,
2011).
In vitro terminal differentiation of DARPP32-positive striatal
neurons from hESCs was first described in 2008 (Aubry et al.,
2008), using SHH and DKK1 to promote ventral telencephalic
neuronal differentiation. A major improvement was recently pub-
lished by Zhang and colleagues (Ma et al., 2012) who succeeded
in identifying the optimal time and dosage of SHH signals (SHH
itself or purmorphamine). Starting from hESCs, Ma et al.
produced lateral ganglionic eminence (LGE) neural precursors
that predominantly differentiated into DARPP32-expressing
GABAergic neurons, with up to 90% and 81% of GABA and
DARPP32-positive cells, respectively, and featured appropriate
neuronal characteristics as determined by HPLC and whole-
cell patch-clamp. Beyond in vitro protocol validation, evaluation
of the survival, maturation, integration, and ultimately function of
engrafted hESC-derived striatal neurons is crucial in order to
assess the feasibility of such an approach. Earlier transplantation
experiments showed high yield of hESC-derived DARPP32-
positive neurons mixed with massively overproliferating neural
progenitor cells (Aubry et al., 2008). The study by Zhang and
colleagues represents a major improvement because it demon-
strated that hESC-derived striatal grafts could integrate into the
host neural circuitry and correct motor deficits in a rodent model
of striatal neurodegeneration (Parmar and Bjo¨rklund, 2012). The
authors also reported a high yield of GABA/DARPP32-positive
neurons in vivo. In addition, there was no sign of massive over-
growth or tumor formation up to 16 weeks after transplantation.
The graft-derivedGABAergic projection neuronswere integrated
into the host neural circuitry, receiving dopaminergic inputs from
the midbrain and glutamatergic inputs from the cortex while pro-
jecting fibers to the substantia nigra. This extensive integration is
consistent with the functional rescue seen, as compared to
control transplants of spinal neurons.
At present, hESCs are still the only type of hPSCs available as
clinical grade lines. They are currently being used in several
clinical trials for Retinal Pigmented Epithelial cell therapy. In the
context of HD cell therapy, hESCs are thus a first choice as
a starting material. The derivation of patient-specific iPSCs for
regenerative medicine is often cited as the optimal situation,
due to concerns over immunological tolerance. In this issue of
Cell Stem Cell, An et al. demonstrate a proof of principle for
the potential use of autologous iPSCs in HD therapy through
genetic correction in patient-derived iPSCs. This approach is
appealing because patient-derived striatal neurons with muta-
tions that were corrected before transplantation would not be
subjected to cell-intrinsic neurodegenerative signals that would
ultimately limit the long-term viability of the graft. However, the
need for genetic correction of the HD mutation adds substantial
complications to clinical HD therapy protocols, including the
screening of several hundred clinical-grade iPSC clones to
isolate genetically corrected ones and the regulatory burden of
combining gene therapy with cell therapy. With current genetic
engineering technologies, these factors limit the economic
viability of this type of approach. A more pragmatic alternative
may be the construction of iPSC banks containing haplotyped
cell lines homozygous for the major HLA antigens, A, B, and156 Cell Stem Cell 11, August 3, 2012 ª2012 Elsevier Inc.DR, with the underlying rationale that a few lines presenting the
most common HLA haplotypes could cover a large fraction of
the population (Gourraud et al., 2012; Taylor et al., 2005,
2012). Protocols for direct lineage conversion between distantly
related cells (e.g. a skin fibroblast into a neuron) (Chambers
and Studer, 2011; Yang et al., 2011) may yet provide another
alternative source in the future. While the direct derivation of
postmitotic human neurons has little practical bearing on HD
cell therapy, particularly because of the number of cells required,
the conversion of somatic cells into multipotent and self-
renewing neural progenitor cells (iNSCs/iNPCs) could be more
fruitful (Han et al., 2012; Lujan et al., 2012; Ring et al., 2012; Thier
et al., 2012). If this technology can be used to produce a human
striatal neuron progenitor population, it could provide a new way
to access self-renewable human striatal cells that may require
less extensive or even no in vitro differentiation before being
considered for transplantation into an HD brain.
Beyond the proof of principle that hESC derivatives can repair
the brain of HD mice, several key challenges need to be
addressed to translate these achievements into clinical applica-
tions. Experimental analysis will be needed to refine the size and
composition (projection neurons versus interneurons) of the
optimal hPSC-derived grafts for HD. In addition, confirmation
that the symptomatic improvement observed is long lasting
and covers both motor and cognitive behaviors will also be
necessary. The unpredictable nature of xenotransplantation
experiments in small and immunocompromised rodent models
of HD is a noteworthy concern. The simple difference in size of
the striatum between rodents and humans dramatically changes
both the extent of proliferation of hPSC-derived cells that would
be required and the distance that graft-derived neurites would
need to cover to reconnect distant target structures. Alloimmuni-
zation to donor antigens (>50% of HD patients in a phase II
multicenter study), occasionally resulting in immune rejection
of fetal neural grafts, has been reported in HD patients (Capetian
et al., 2009;Cicchetti et al., 2009;Gallina et al., 2008;Krystkowiak
et al., 2007), raising concerns about potential immunological
responses to hPSC-derived grafts. These concerns are strength-
ened by the suggestion that abnormal gene expression in some
cells differentiated from iPSCs may induce a T cell-dependent
immune response in syngeneic recipients (Zhao et al., 2011).
The need for long-term in vivo followup and more extensive
cognitive testing combined with the issues that arise from
size differences and immunological responses all argue for
preclinical HD cell therapy research in large animals. The best
way to model future clinical setup would be to use nonhuman
primate models of HD tested with an allogeneic source of PSCs.
When considering the use of hPSC derivatives in HD patients,
safety concerns become even more prominent than when fetal
tissues are utilized. Issues raised by regulatory agencies often
include the potential for unwanted growth and differentiation of
hPSC-derived grafts, the potential unpredictability of such cells,
and the challenges associating with removing potentially harmful
cells or monitoring them for harmful effects. The straightforward
and accepted strategy to tackle these issues is to refine the
differentiation protocols to optimize efficiency, and perform
extensive quality control. It is, however, unclear whether regula-
tory bodies around the world will require different or more strin-
gent controls. For example, one possibility could be requiring
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containing a suicide gene that could be activated if necessary.
In summary, PSC technologies have been successfully
applied to experimental HD cell therapy in animal models. Proto-
cols for the derivation of striatal progenitors from hPSCs provide
access to therapeutically relevant graftingmaterial. Furthermore,
the proof of principle that stem cell-based HD cell therapy can
achieve some degree of functional striatal repair in a mouse
model of HD has been established. The next steps are to apply
these advances in more clinically relevant nonhuman primate
models and tackle the safety issues involved.
Human PSCs for Gene Therapy Validations
A number of other potential therapeutic interventions are strictly
specific to human cells or tissue, such as biotherapies based
upon targeting human gene/mutation with RNA interference,
RNA trans-splicing (exon skipping), and therapeutic antibodies.
With these approaches, the use of classic animal models of
HD for experimental or preclinical validation is not necessarily
particularly informative. Obtaining sufficient cellular material to
conduct a wide range of tests, from the initial assessment of
therapeutic claim to the final quality assurance process before
clinical batch release, can be challenging. With the exception
of the rare cases when partially humanized animal models can
be used, analyses require patient-derived cells of a relevant
cell type (e.g. neurons, astrocytes etc.) ideally presenting an
impaired phenotype that is reminiscent of the pathology. For
obvious reasons, access to HD human brain cells is limited to
postmortem samples. However, HD-specific hPSC neural deriv-
atives are an ideal candidate to overcome the lack of HD human
neural cells and could be used for the development of human-
specific therapeutic interventions for HD.
Gene therapy for HD is often aimed at providing neurotrophic
factors (BDNF, NT-3, NT-4/5, FGF, GDNF, and CNTF) known to
promote neuronal survival. An alternative approach is to inhibit
the expression of the mutant HTT protein instead. Short of
achieving genomic correction of brain cells, as in the study
from Ellerby and colleagues (An et al., 2012), this alternative
approach directly targets the first product of the mutation, i.e.
HTT mRNA, either allele-specifically (mutant only) or not. This
type of therapy is based on the use of antisense oligonucleotides
(e.g. shRNA, small synthetic nucleic acid molecules) directed
against the mRNA of HTT to prevent its translation (Matsui and
Corey, 2012). Encouragingly, HTT RNA interference directed
against mutantHTT reducesHTTmRNA and protein expression.
HTT gene silencing in the HD mouse brain resulted in reduced
motor deficits and prolonged survival of animals (Harper et al.,
2005; Kordasiewicz et al., 2012). Inhibition of HTT expression
in the adult brain does not seem to cause detectable dysfunc-
tion, but the consequences of long-term HTT silencing in the
adult human brain remain unclear. Research in this field has
now moved toward the development of ‘‘allele-specific RNA
interference.’’ The corresponding synthetic molecules, or their
equivalent vectors, are designed to reduce the expression of
mutant HTT protein but leave normal HTT levels mostly
unchanged. Several preclinical programs are underway, some
in biotechnology companies (e.g., Alnylam Pharmaceuticals
[Stiles et al., 2012], Prosensa). The efficacy of RNA interference
may vary depending on the basal expression level of the genebeing targeted. Although HTT expression is ubiquitous, HTT
mRNA levels in the adult are largely cell type specific. In fibro-
blasts or lymphocytes, two cell types that can be retrieved
from living HD patients, HTT mRNA levels are more than 100
times lower than that in cortical or striatal neurons, the intended
target cells (Feyeux et al., 2012), making them less suitable as
a basis for testing and experimentation. The advantages of
neural derivatives of HD-hPSCs over other cellular models are
3-fold. First, HD-hPSC derivatives carry the exact genomic
content relevant for HTT, i.e. a single mutant HTT allele and
a single wild-type allele. Second, HD-hPSCs provide unlimited
access to phenotypically relevant cells, including postmitotic
neurons, which express HTT at significantly higher levels than
fibroblasts. Third, HD-hPSC neural derivatives feature muta-
tion-induced functional impairments (see Table 1), and correc-
tion of these phenotypes using gene therapy or other human-
specific biotherapies may be a unique way of testing their actual
value as a therapeutic agent before clinical trials.
Taken together, human PSCs and neural derivatives represent
an interesting cellular platform for assaying potential therapeutic
agents that interfere with cell-autonomous mechanisms of HD.
Nevertheless, complementary approaches using in vivo animal
models should also be used to investigate systemic effects
that are essentially beyond the reach of in vitro studies.
Exploring Molecular Mechanisms of HD Using Human
PSC Lines
Before the advent of iPSC technology (Takahashi et al., 2007),
embryos characterized as mutant-gene carriers during a preim-
plantation genetic diagnosis procedure were the only source for
PSC-based disease modeling studies. A number of HD mutant
hESC lines have been obtained for HD by various laboratories
(Feyeux et al., 2012), with triplet repeats of a common length
for the adult onset form of the disease (40 to 51). Human iPSC
lines have also now been added to the mix, including some
with repeat lengths associated with juvenile forms of the disease
(Park et al., 2008), or rare and extreme genotypes including some
with up to 180 repeats (The HD iPSC Consortium, 2012) or
a homozygous HD mutation (Camnasio et al., 2012). Selection
of donors with discrete genotype/phenotype associations (e.g.,
with similar CAG repeat length but very different age of clinical
onset) may eventually help identify modifier genes (Table 1).
Outside the HD field itself, disease modeling using PSCs only
began a few years ago, with the first major breakthroughs
using ESCs occurring in 2007 (Eiges et al., 2007). However,
this approach has gained significant momentum since then,
mostly as a result of the availability of iPSC lines from affected
donors. Even though this area is still relatively new, a few conclu-
sions are possible. Most publications to date have reported the
replication of known pathological mechanisms at the molecular
level. This step was necessary for validating the general princi-
ples, but has been slightly frustrating, in particular when the
only outcome of a publication was the very existence of an
iPSC line. These preliminary studies are now giving way to the
search for mechanisms that shed new light on functional and
clinical correlates of the disease (for example, see Lee et al.,
2009; Marteyn et al., 2011).
One key issue for iPSC disease-modeling studies is the rele-
vance of the results to the disease process. Demonstrating thisCell Stem Cell 11, August 3, 2012 ª2012 Elsevier Inc. 157
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complex with diseases that generally have a late clinical onset,
like HD. A first challenge is the actual relevance of the cell model
in terms of ‘‘age equivalence.’’ Human ESCs and iPSCs are, in
principle, only a few days old in terms of ‘‘developmental age,’’
and the cells derived from them through differentiation frequently
resemble embryonic rather than adult populations. Although
in vitro chronobiology may differ from (i.e. be somewhat faster
than) its in vivo counterpart, this is clearly an important issue to
consider. For example, the relevant genesmay not be expressed
at an early developmental stage, and RNA processing may be
controlled differently in the embryo and adult. As the neural
derivatives of PSCs, even if they are postmitotic, should be
considered relatively immature, their relevance to development
beyond embryonic and fetal stages cannot be extrapolated
without specific validation. With regard to HD, it is important to
note that expression of the HTT gene in postmitotic neurons
derived fromPSCs ismuch lower than that seen in the adult brain
(Feyeux et al., 2012).
A second important issue to consider is the functional
outcome of the mutation. PSCs offer the opportunity to study
disease mechanisms in a dish. However, as a corollary, the
model that they provide is very strongly biased toward cell
autonomous mechanisms, which is a conspicuous limitation
for most diseases. For example, in the case of HD, it may be diffi-
cult to validate transcriptomic results obtained with PSCs in vitro
by comparing them with transcriptomic analyses of patient-
derived brain or blood cells. This type of analysis should be
viewed against the backdrop of general concerns about the
lack of well-established protocols for global comparisons of
whole-genome transcriptomic data. In studies of HD, compari-
sons of data generated within a single laboratory have been
successful in demonstrating significant overlap between tran-
scription changes observed in several HD mouse models and
human HD caudate (Kuhn et al., 2007; Becanovic et al., 2010).
However, transcriptomic studies of HD patient blood samples
conducted in two distinct laboratories, yet using similar sample
size and Q-PCR primer pairs, produced totally divergent results
(Borovecki et al., 2005; Runne et al., 2007). A second concern is
the fact that stage-dependent neuronal death as well as glial
proliferation and death in HD dramatically affect the cellular
composition of HD brain tissues relative to ostensibly equivalent
healthy tissue. Transcriptomic changes detected in human brain
samples would therefore also reflect differences in cellular
composition. Newly developed bioinformatic tools have promp-
ted the field to reconsider previously published data and conclu-
sions in depth (Becanovic et al., 2010; Kuhn et al., 2011), and
hopefully further development and refinement of algorithms will
ameliorate some of these problems. Another important consid-
eration is that most studies of human samples have involved
brain tissue from patients who were clinically affected and thus
have strong bias toward end-stage disease. However, hPSC-
derived neurons would not exhibit such alterations because
they would not reflect aged neurons. Indeed, ‘‘developmental
age equivalent’’ cells that are a few weeks or months old in utero
are in principle healthy enough to build an individual who would
not show overt signs of the disease for some time. Cells that
display a large deviation relative to healthy controls in terms of
the number of differentially expressed genes, or proliferation158 Cell Stem Cell 11, August 3, 2012 ª2012 Elsevier Inc.and differentiation capacities, likely do not replicate the progres-
sion of HD in an individual who would be clinically affected only
years, and most often decades, after birth.
So, What Can PSC Neural Derivatives Tell Us about HD?
Because they are human cells, hPSC-derived neural cells
provide scientists with a unique biological platform to investigate
the molecular mechanisms involved in the disease using both
hypothesis-driven and exploratory approaches. A number of
proteins and signaling pathways have been identified using other
models, with potential roles in the cellular pathogenesis associ-
ated with HD. PSC neural derivatives offer a way to test those
hypothetical mechanisms within the framework of a human cell
that physiologically replicates a number of characteristics of
the neural cells that are affected by the disease (Table 1). There
is no need here for a comparison of the relative value between
this type of model and those that have been used up to now:
hPSC neural derivatives are at a minimum complementary to
previous models that were not of human origin, genetically
altered, and/or not of the neural lineage.
Although, as discussed above, hPSC-derived neural cells
have limitations associated with their equivalence to relatively
early stages of development, this caveat can also be turned
around and used as an asset as it provides a way to study the
very early cellular consequences of mutant HD gene expression.
Indeed, one could consider that rather than offering a good way
to explore pathological mechanisms associated with neuronal
dysfunction and damage, PSC neural derivatives provide an
opportunity for analyzing how cells cope with the HD mutation
and escape dysfunction and damage for decades. Although
establishment of a strong conceptual framework for such an
analysis is awaiting relevant data, it may be fruitful to apply to
HD the concept of ‘‘pathways of toxicity’’ that has recently
emerged in a completely different field, predictive toxicology
(National Research Council, 2007). In that field, major efforts
have been directed at tackling the vexing problems caused
by the inability of current practices, which rely on testing
of acute toxic effects, to reliably predict the chronic toxicity
of the acute-tested compounds. Toxicologists have come to
the conclusion that the mechanisms leading to these two
phenomena are most likely different. Although acute toxicity
directly triggers various death pathways, chronic toxicity is char-
acterized by molecular changes that together form so-called
pathways of toxicity. The first step occurs through alteration
(by the toxicant) of one or more physiological signaling path-
ways, in turn inducing a second pathway designed to bypass
the original defect in the first pathway. Thus, in the early stages
of a toxic impact, the outcome is a combination of several molec-
ular modifications in the affected cell: (1) an ‘‘original’’ alteration
in the activity of a signaling pathway, (2) the triggering of ‘‘danger
signaling’’ systems, and (3) bypass of the alteration via compen-
satory mechanisms. Extrapolating that scheme to mutant HD
protein, which is considered to be a chronic toxicant, PSC neural
derivatives may provide us with a biological platform to identify
the three components of a similar system responsible for the
very long-term healthy survival of affected neurons (Figure 2).
Limiting the original impact and promoting compensatory path-
ways may, as a consequence, become therapeutic goals in
order to delay or prevent clinical onset in patients with the HD
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Perspectivemutation. In contrast, HD mutants with triplet repeat lengths
exceeding the usual disease range, in particular exceptional
ones over 100 CAGs, may be triggering acute deleterious conse-
quences, similar in that sense to an acute toxic hit. In those latter
cases, therapeutic agents opposing cell death pathways may
well be the only ones that would be effective.
Using Human PSC Lines for Drug Discovery in HD
Historically the limited size of the HD patient population, which is
several orders of magnitude smaller than that of major nonin-
herited neurological disorders such as Alzheimer’s disease,
has limited investments in HD drug discovery by biotech and
pharmaceutical companies, leaving academic labs and patient
associations as the main players in the field. Recent renewed
interest in HD from the pharmaceutical industry stems from
a conceptual shift about the disease: HD is no longer considered
primarily as a rare genetic disease, but rather, as a paradigmatic
neurodegenerative disorder that could provide insights that
would also be relevant for more prevalent diseases such as
Alzheimer’s and Parkinson’s disease (Leegwater-Kim and Cha,
2004). The rationale for this shift is 2-fold: (1) HD has a genetic
link that more prevalent but less understood neurodegenerative
disorders are still lacking, and (2) HD features major pathophys-
iological hallmarks that are also seen in these multigenic
and/or multifactorial diseases, including progressive and selec-
tive neuronal death, transcriptional dysregulation, mitochondrial
dysfunction, and protein aggregation.
The development of patient- and disease-specific PSCs
further accentuates this shift because it gives a new perspective
on cell-based high-throughput screening (HTS) and high-
content screening (HCS) for HD. HTS can be defined as the
process in which many chemical molecules are tested for their
biological activity on a given target molecule or a particular
phenotype. HTS usually involves the screening of thousands of
compounds simultaneously. HCS is usually but not necessarilyCell Stem Cell 1placed downstream of HTS sequences
(primary, secondary HTS, etc.), and
involves more complex, information-rich
(and thus slower and more expensive)
assays than HTS. HTS technologies
applied to proprietary libraries exceeding
one million synthetic small molecules
from the larger pharmaceutical compa-
nies have identified a wealth of primary
hits and lead compounds across a
broad range of diseases. Unfortunately
the maximum flowthrough of the drug
discovery pipeline has remained mostly
unchanged due to the paralleled increase
in the dropout rate during drug develop-
ment. This disappointment has applied
to HD drug discovery as well, and prom-
ising drugs counteracting common HDphenotypes (aggregation, caspase activity, and cell death)
have emerged only to fail at the finish line, i.e. in phase I or II
clinical trials, having mobilized a significant fraction of the limited
HD patient population in vain. Cell-based assays for phenotypic
HTS have been introduced in an attempt to limit the considerable
cost of drug attrition. Cell-based assays are thought to be
‘‘more physiological systems’’ than target-oriented biochemical
assays, but they also present a dilemma for the HTS community
concerning the source of the cellular material to be used. On one
hand, primary cells are relevant in terms of phenotype but they
are available in limited and poorly standardized supply from
patient biopsy or animal model dissection. Immortal lines
derived from these primary cultures are standardized and
scalable, but their phenotype often lacks relevance and may
be confused by compensatory mutations obtained during
immortalization (An and Tolliday, 2009).
The availability of patient- or disease-specific PSCs and their
derivatives has completely moved the goal posts for this
dilemma. Indeed, with derivatives of such cells, standardization
and scaling-up capacities can be combined with the availability
of highly relevant phenotypes. Protocols developed in the
context of cell therapy or pathological modeling programs now
offer direct access to proliferative human neural stem cells as
well as region/subtype-specific postmitotic neurons (reviewed
in Liu and Zhang, 2011). This unique and unlimited access to
relevant phenotypes in itself constitutes a major improvement
over primary or immortalized cells for HTS. Appropriate rescaling
leading to the development of large cell banks of hPSCs and their
neural derivatives could provide consistent cell preparations
necessary for multiple screening campaigns. In addition to
scale-up capacity and phenotypic relevance, patient-specific
hPSCs also provide genotypic relevance. This aspect raises
the possibility of finding drugs of interest and then later assess-
ing the range of responsiveness in human subpopulations. The
sizes of these subpopulations range from an entire ethnic group1, August 3, 2012 ª2012 Elsevier Inc. 159
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Perspectiveto diseasemutation carriers and ultimately to individuals carrying
both the disease mutation and unknown genetic modifiers
that significantly change the age of onset of the genetic disease.
In the particular context of HD, HTS- or HCS-compatible
assays can be aimed at a known phenotype or target newly iden-
tified mechanisms uncovered through pathological modeling
programs (see Table 1).
Overall, the expectation is that human PSC-based perspec-
tives of ‘‘disease in a dish’’ may soon reduce obligatory preclin-
ical testing in nonpredictive animal models and ultimately be
reflected in increased success with clinical trials testing lead
compounds (Grskovic et al., 2011). This overall drug discovery
strategy has already been applied to target other neurodegener-
ative diseases. One example is an HCS approach used by
iPerian to screen for drugs capable of normalizing SMN-impaired
expression levels in motor neurons generated from iPSCs from
type 1 SMA patients (Grskovic et al., 2011). Later in the drug
discovery cascade, a second use of patient-derived PSCs could
be to improve the prediction power of animal models. For
example, transplantation of HD-iPSC derivatives with homotopic
grafting of striatal or cortical neurons could provide new human-
ized animal models for testing in vivo efficacy of potential drugs.
In the context of HD drug discovery, HD-hPSCs have not yet
been harnessed using this type of integrated stem cell strategy.
As discussed above, it is likely that HD stem cell based drug
discovery will generate the most significant advances by aiming
at different targets than those previously studied (caspase 3, cell
death, HTT aggregates, etc.; for review, see (Varma et al., 2011).
The added value of HD-hPSC derivatives probably lies, as out-
lined above, in their potential for indicating mutation-triggered
‘‘danger signals’’ and compensatory processes. HD-PSCs could
therefore allow HD screening for drugs capable of both limiting
the original impact of the HD mutation and promoting compen-
satory recovery pathways in human brain cells.Conclusion
The search for mechanisms and treatments of HD has pro-
gressed substantially since the first genomic findings in the
1980s. Awealth of studies have since then shed light on potential
molecular and cellular mechanisms. Cell therapy still lacks
conclusively proven efficacy but is nevertheless the only thera-
peutic forwhich a successful clinical outcomehasbeen reported.
In parallel, progress has also been made in identifying chemical
compounds that counteract disease pathology, but so far these
have unfortunately not been effective when tested in patients,
evenwhen they have given partial amelioration of disease pheno-
types in animal models. The lack of a relevant human neural cell
model ofHDhasbeenhighlighted asoneof themost likely causes
for this discrepancy between experimental and clinical data. The
development of stem cell technologies and the appearance of
a number of human PSC lines that demonstrate pathological
mechanisms linked to the disease will hopefully contribute to
solving some of these problems in the near future.REFERENCES
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